Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors

Hyun Il Cho, Guilian Niu, Norma Bradley, Esteban Celis

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Vaccines capable of inducing CD8 T cell responses to antigens expressed by tumor cells are considered as attractive choices for the treatment and prevention of malignant diseases. Our group has previously reported that immunization with synthetic peptide corresponding to a CD8 T cell epitope derived from the rat neu (rNEU) oncogene administered together with a Toll-like receptor agonist as adjuvant, induced immune responses that translated into prophylactic and therapeutic benefit against autochthonous tumors in an animal model of breast cancer (BALB-neuT mice). DNA-based vaccines offer some advantages over peptide vaccines, such as the possibility of including multiple CD8 T cell epitopes in a single construct. Materials and methods: Plasmids encoding a fragment of rNEU were designed to elicit CD8 T cell responses but no antibody responses. We evaluated the use of the modified plasmids as DNA vaccines for their ability to generate effective CD8 T cell responses against breast tumors expressing rNEU. Results: DNA-based vaccines using modified plasmids were very effective in specifically stimulating tumor-reactive CD8 T cell responses. Moreover, vaccination with the modified DNA plasmids resulted in significant anti-tumor effects that were mediated by CD8 T cells without the requirement of generating antibodies to the product of rNEU. Conclusions: DNA vaccination is a viable alternative to peptide vaccination to induce potent anti-tumor CD8 T cell responses that provide effective therapeutic benefit. These results bear importance for the design of DNA vaccines for the treatment and prevention of cancer.

Original languageEnglish (US)
Pages (from-to)1695-1703
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume57
Issue number11
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

DNA Vaccines
Breast Neoplasms
T-Lymphocytes
Plasmids
Vaccination
T-Lymphocyte Epitopes
Neoplasms
Therapeutics
Peptides
Subunit Vaccines
Toll-Like Receptors
DNA
Neoplasm Antigens
Oncogenes
Antibody Formation
Immunization
Vaccines
Animal Models
Antibodies

Keywords

  • Animal models
  • Breast cancer
  • CD8 T cells
  • DNA vaccines
  • HER2/neu

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors. / Cho, Hyun Il; Niu, Guilian; Bradley, Norma; Celis, Esteban.

In: Cancer Immunology, Immunotherapy, Vol. 57, No. 11, 01.11.2008, p. 1695-1703.

Research output: Contribution to journalArticle

@article{472198d625c248d5b016e492290dd8e0,
title = "Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors",
abstract = "Background: Vaccines capable of inducing CD8 T cell responses to antigens expressed by tumor cells are considered as attractive choices for the treatment and prevention of malignant diseases. Our group has previously reported that immunization with synthetic peptide corresponding to a CD8 T cell epitope derived from the rat neu (rNEU) oncogene administered together with a Toll-like receptor agonist as adjuvant, induced immune responses that translated into prophylactic and therapeutic benefit against autochthonous tumors in an animal model of breast cancer (BALB-neuT mice). DNA-based vaccines offer some advantages over peptide vaccines, such as the possibility of including multiple CD8 T cell epitopes in a single construct. Materials and methods: Plasmids encoding a fragment of rNEU were designed to elicit CD8 T cell responses but no antibody responses. We evaluated the use of the modified plasmids as DNA vaccines for their ability to generate effective CD8 T cell responses against breast tumors expressing rNEU. Results: DNA-based vaccines using modified plasmids were very effective in specifically stimulating tumor-reactive CD8 T cell responses. Moreover, vaccination with the modified DNA plasmids resulted in significant anti-tumor effects that were mediated by CD8 T cells without the requirement of generating antibodies to the product of rNEU. Conclusions: DNA vaccination is a viable alternative to peptide vaccination to induce potent anti-tumor CD8 T cell responses that provide effective therapeutic benefit. These results bear importance for the design of DNA vaccines for the treatment and prevention of cancer.",
keywords = "Animal models, Breast cancer, CD8 T cells, DNA vaccines, HER2/neu",
author = "Cho, {Hyun Il} and Guilian Niu and Norma Bradley and Esteban Celis",
year = "2008",
month = "11",
day = "1",
doi = "10.1007/s00262-008-0465-x",
language = "English (US)",
volume = "57",
pages = "1695--1703",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "11",

}

TY - JOUR

T1 - Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors

AU - Cho, Hyun Il

AU - Niu, Guilian

AU - Bradley, Norma

AU - Celis, Esteban

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Background: Vaccines capable of inducing CD8 T cell responses to antigens expressed by tumor cells are considered as attractive choices for the treatment and prevention of malignant diseases. Our group has previously reported that immunization with synthetic peptide corresponding to a CD8 T cell epitope derived from the rat neu (rNEU) oncogene administered together with a Toll-like receptor agonist as adjuvant, induced immune responses that translated into prophylactic and therapeutic benefit against autochthonous tumors in an animal model of breast cancer (BALB-neuT mice). DNA-based vaccines offer some advantages over peptide vaccines, such as the possibility of including multiple CD8 T cell epitopes in a single construct. Materials and methods: Plasmids encoding a fragment of rNEU were designed to elicit CD8 T cell responses but no antibody responses. We evaluated the use of the modified plasmids as DNA vaccines for their ability to generate effective CD8 T cell responses against breast tumors expressing rNEU. Results: DNA-based vaccines using modified plasmids were very effective in specifically stimulating tumor-reactive CD8 T cell responses. Moreover, vaccination with the modified DNA plasmids resulted in significant anti-tumor effects that were mediated by CD8 T cells without the requirement of generating antibodies to the product of rNEU. Conclusions: DNA vaccination is a viable alternative to peptide vaccination to induce potent anti-tumor CD8 T cell responses that provide effective therapeutic benefit. These results bear importance for the design of DNA vaccines for the treatment and prevention of cancer.

AB - Background: Vaccines capable of inducing CD8 T cell responses to antigens expressed by tumor cells are considered as attractive choices for the treatment and prevention of malignant diseases. Our group has previously reported that immunization with synthetic peptide corresponding to a CD8 T cell epitope derived from the rat neu (rNEU) oncogene administered together with a Toll-like receptor agonist as adjuvant, induced immune responses that translated into prophylactic and therapeutic benefit against autochthonous tumors in an animal model of breast cancer (BALB-neuT mice). DNA-based vaccines offer some advantages over peptide vaccines, such as the possibility of including multiple CD8 T cell epitopes in a single construct. Materials and methods: Plasmids encoding a fragment of rNEU were designed to elicit CD8 T cell responses but no antibody responses. We evaluated the use of the modified plasmids as DNA vaccines for their ability to generate effective CD8 T cell responses against breast tumors expressing rNEU. Results: DNA-based vaccines using modified plasmids were very effective in specifically stimulating tumor-reactive CD8 T cell responses. Moreover, vaccination with the modified DNA plasmids resulted in significant anti-tumor effects that were mediated by CD8 T cells without the requirement of generating antibodies to the product of rNEU. Conclusions: DNA vaccination is a viable alternative to peptide vaccination to induce potent anti-tumor CD8 T cell responses that provide effective therapeutic benefit. These results bear importance for the design of DNA vaccines for the treatment and prevention of cancer.

KW - Animal models

KW - Breast cancer

KW - CD8 T cells

KW - DNA vaccines

KW - HER2/neu

UR - http://www.scopus.com/inward/record.url?scp=50649084152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50649084152&partnerID=8YFLogxK

U2 - 10.1007/s00262-008-0465-x

DO - 10.1007/s00262-008-0465-x

M3 - Article

C2 - 18253731

AN - SCOPUS:50649084152

VL - 57

SP - 1695

EP - 1703

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 11

ER -